ORIGINAL ARTICLE

Prognosis after steroid pulse therapy and seasonal effect in acquired idiopathic generalized anhidrosis

Tadatsune IIDA,1,* Michiko NAKAMURA,1,* Minako INAZAWA,1 Takichi MUNETSU1,1, Makiko NISHIDA,1 Tomoko FUJIMOTO,1 Yoshiyuki SASAKI,2 Yuichiro OSHIMA,3 Yoshihiko NAKAZATO,4 Takeshi NAMIKI,1, HIROO YOKOZEKI1

1Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 2Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 3Department of Dermatology, Aichi Medical University School of Medicine, Nagakute, 4Department of Neurology, Saitama Medical University, Moroyama, Japan

ABSTRACT

Acquired idiopathic generalized anhidrosis is a rare disease with unknown etiology. Sudden loss of sweating function adversely affects young patients’ quality of life. Although systemic corticosteroid therapy is the most frequently reported treatment for the disease, its effectiveness is controversial because of the risk of recurrence. To assist clinical decision-making regarding whether to use steroids, we investigated the treatment responsiveness and recurrence rates in patients undergoing steroid pulse therapy and explored factors affecting these rates. We retrospectively collected data of 124 patients who received steroid pulse therapy to calculate the rate of responsiveness to the therapy. We also conducted a time-to-event analysis in a cohort of 57 patients who responded to steroid pulse therapy to estimate the recurrence rate after the therapy. As a result, the response and recurrence rates were 73% and 48%, respectively. Recurrence occurred within 1 year in most patients. The overall effectiveness of steroid pulse therapy was estimated to be 57% considering the recurrence rate. A delay from onset to treatment and younger age appeared to be negative factors for effectiveness. Moreover, we found a significant seasonal effect on both treatment and recurrence: autumn was the worst season for acquired idiopathic generalized anhidrosis in Japan. Our study revealed that steroid pulse therapy can be expected to be effective in half of treated patients. We recommend starting the therapy promptly after the diagnosis; however, it is also worth considering the season for treatment planning.

Key words: cohort studies, hypohidrosis, sweat glands, temperature, urticaria.

INTRODUCTION

Acquired idiopathic generalized anhidrosis (AIGA) is a rare and refractory disease with unknown etiology and mainly occurs in young men.1 The main symptom is impairment of sweating, which limits patients’ activity in hot environments and strongly affects quality of life.2 Most cases of AIGA have been reported in Asia, especially Japan.1,3,4 The cause of the disease has not been determined, but studies have suggested that immunological mechanisms may be involved in the impairment of sweating.5–7 Although some cases of AIGA are cured spontaneously, most appear to become intractable after a certain time without treatment.3,8,9 Systemic steroid treatment is the most frequently reported treatment for AIGA, but its effectiveness has not been sufficiently evaluated. Several reports have indicated considerable effectiveness of steroids for improvement of sweating function,5,6,8,10 but complete ineffectiveness has also been reported in some patients.3,11,12 Furthermore, a high recurrence rate after the therapy has been reported.6,13 All such information to date has been obtained from case reports or small case series;6,14,15 no study has been performed to estimate treatment effectiveness considering both the response and recurrence rates. In addition, although several factors have been suggested to influence the prognosis, including age, sex and duration from onset to treatment, these findings were not supported by statistics.3,13 Knowledge of the precise treatment effectiveness with consideration of the recurrence rate as well as identification of prognostic factors would be helpful for determining whether to use steroids in patients with AIGA.

Correspondence: Hiroo Yokozeki, M.D., Ph.D., Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. Email: 3064derm@tmd.ac.jp

*These authors contributed equally to this work.

Received 8 July 2020; accepted 28 September 2020.

© 2020 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
To estimate the true effectiveness of steroid therapy in patients with AIGA, we collected data from 124 patients treated with steroid pulse therapy and retrospectively examined their responsiveness to the treatment. We then investigated the recurrence rate among 57 patients who responded to the therapy. Further, we explored prognostic factors affecting the treatment effectiveness.

METHODS

Ethics
We conducted this study according to the principles of the Declaration of Helsinki. The study was approved by the ethics committees of Tokyo Medical and Dental University, Saitama Medical University, and Aichi Medical University hospitals.

Responsiveness to steroid pulse therapy
To assess the responsiveness to the therapy, we retrospectively collected data from all patients with AIGA who received pulse therapy with 3-day i.v. methylprednisolone (0.5–1.0 g/day) at Tokyo Medical and Dental University hospital from April 2008 to May 2019, Saitama Medical University hospital from January 2015 to December 2018, and Aichi Medical University hospital from November 2015 to March 2017. The patients’ age at start of treatment, sex, medical history, diagnostic and follow-up examinations, and clinical course were obtained from the medical records. We confirmed the diagnosis of AIGA in accordance with the Japanese guideline. Patients were judged as responders to the therapy if the body surface area with perspiration had increased by more than 25% at 1 month after the pulse therapy. This area of increased perspiration was estimated based on a medical interview 1 month after the therapy and, in some patients, a subsequent starch-iodine test (the accuracy of interviews is assessed in Table S6). When patients received multiple courses of pulse therapy, those who met the criteria at least once were grouped as responders; the remaining patients were grouped as non-responders. We adopted 25% as the threshold according to the criteria for scoring disease severity described in the Japanese guideline (area of hypohidrosis or anhidrosis scored as follows: 1, 25%–49%; 2, 50%–74%; and 3, 75%–100%). This score reportedly has a good correlation with quality of life. In this analysis, we did not consider whether the patients developed recurrence after the therapy; that is, we grouped all of the patients with recurrence as responders. We also explored whether the patients’ characteristics affected the responsiveness.

We examined the effect of each course of pulse therapy by using the data of patients from Tokyo Medical and Dental University hospital. We analyzed the influence of several factors on the responsiveness to each course of pulse therapy, including post-treatment (oral prednisolone after the 3-day pulse), number of courses, season and interval from the previous course (Table 2). We compared the rate of responsiveness between every possible pair of months for more precise investigation on the seasonal effect (Fig. 1b, Table S2). We also computed the correlation between the monthly rate of effectiveness and the mean temperature, and the correlation between the monthly rate of effectiveness and the mean humidity in Tokyo, Japan, in 2019. The rate of responsiveness for each number of courses of pulse therapy was calculated separately for responders without recurrence (further grouped according to the total number of courses performed), responders with recurrence and non-responders (Table S3). We also investigated adverse effects for each course of steroid pulse therapy (Table S4).

Recurrence after steroid pulse therapy
To estimate the recurrence rate after successful steroid pulse therapy, we conducted a retrospective cohort study using the data of the patients who had responded to the pulse therapy from Tokyo Medical and Dental University hospital. Time zero was set to the 3rd (final) day of the last course of steroid pulse therapy, and the observation was censored at the time of recurrence or the end of the observation period. Patients were judged to have developed recurrence if the area with perspiration had decreased by more than 25% since the state of remission according the criteria for scoring disease severity. When a patient also received pulse therapy after recurrence, time zero was set to the last day of pulse therapy before the recurrence, and only the initial recurrence was analyzed. The recurrence rate was estimated by the Kaplan–Meier method. We also explored whether the patients’ characteristics affected the recurrence rate by univariate analyses (log-rank test). The optimal threshold value of age was determined by receiver–operator curve analysis with recurrence as the negative label (Fig. S1). A Cox proportional hazards model was applied to compare the young and older groups. We confirmed the assumption of proportional hazards by the log-minus-log of transformed Kaplan–Meier estimates of the survival function (Fig. S2). We compared the patient characteristics between the young and older groups to identify the potential cofounders (Table S5).

The recurrence rate for each season was estimated based on the data from Tokyo Medical and Dental University hospital. According to the Japanese climate, we defined spring, summer, autumn and winter as March–May, June–August, September–November and December–February, respectively. The recurrence rate for each season was calculated as:

\[
\text{Rate} = \frac{N_1}{N_1 + N_2},
\]

where \(N_1\) denotes the number of patients who developed recurrence during the season and \(N_2\) denotes the number of patients who completed observation without recurrence during the season. We deleted duplicate counts of seasons for patients with more than 1 year of follow up.

Estimation of overall effectiveness
We estimated the overall rate of effectiveness of steroid pulse therapy with the following equation:

\[
\text{Rate} = \frac{N_1}{N_1 + N_2},
\]
Effectiveness = \frac{p_1 \times (1 - p_2) + p_1 \times p_2 \times p_3}{p_2}, \quad (2)

p_3 = \frac{n_1}{n_2}, \quad (3)

where $p_1$ denotes the initial response rate for the steroid pulse therapy (Table 1), $p_2$ denotes the estimated recurrence rate during 12 months after the therapy (Figure 3a), $n_1$ denotes the number of patients who responded to the pulse therapy performed after the first recurrence with no subsequent recurrence, and $n_2$ denotes the total number of patients who received pulse therapy after recurrence.

We also estimated the overall rate of effectiveness by a retrospective cohort study using the data of all patients who had undergone pulse therapy at Tokyo Medical and Dental University Hospital (Fig. S4). Time zero was set as the starting day of the first course of steroid pulse therapy. The observation period ended on the day of the last course of steroid pulse therapy for “cured” patients, whose remission periods were confirmed to be longer than 11 months. For “not cured” patients, including responders with a confirmed remission period that did not reach 11 months and non-responders, the end of the observation period was set at 11 months before the last consultation day to exclude the uncertain period during which we could not judge whether the patients had been cured and to minimize selection bias. We excluded data from patients whose observation period was calculated as less than 0 months after the subtraction of 11 months. The cure rate was estimated by the Kaplan–Meier method with not cured as a survival function.

**Statistical analysis**
We performed statistical analyses by Fisher’s test (Tables 1, 2, Table S4, Fig. 2a), the Mann–Whitney U-test (Tables 1, 2, Table S4), paired t-test (Fig. 2c), the log-rank test (Fig. 3b) and the methods specified in the main text. The Benjamini–Hochberg procedure\textsuperscript{17} was utilized with Fisher’s test for multiple hypothesis testing (Figs 2ab, 3c, Table S2). For data processing including computing $P$-values and visualization, we used MATLAB version 2019a software (MathWorks, Natick, MA, USA); for multiple hypothesis testing, however, we used R version 4.0.0 software\textsuperscript{18} with the RVAideMemoire package\textsuperscript{19}.

**RESULTS**

**Responsiveness to steroid pulse therapy**
For precise evaluation of the effectiveness of systemic steroid therapy for AIGA, both the response rate and recurrence rate must be considered. We first examined the response rate to consultation day to exclude the uncertain period during which we could not judge whether the patients had been cured and to minimize selection bias. We excluded data from patients whose observation period was calculated as less than 0 months after the subtraction of 11 months. The cure rate was estimated by the Kaplan–Meier method with not cured as a survival function.

**Statistical analysis**
We performed statistical analyses by Fisher’s test (Tables 1, 2, Table S4, Fig. 2a), the Mann–Whitney U-test (Tables 1, 2, Table S4), paired t-test (Fig. 2c), the log-rank test (Fig. 3b) and the methods specified in the main text. The Benjamini–Hochberg procedure\textsuperscript{17} was utilized with Fisher’s test for multiple hypothesis testing (Figs 2ab, 3c, Table S2). For data processing including computing $P$-values and visualization, we used MATLAB version 2019a software (MathWorks, Natick, MA, USA); for multiple hypothesis testing, however, we used R version 4.0.0 software\textsuperscript{18} with the RVAideMemoire package\textsuperscript{19}.

**RESULTS**

**Responsiveness to steroid pulse therapy**
For precise evaluation of the effectiveness of systemic steroid therapy for AIGA, both the response rate and recurrence rate must be considered. We first examined the response rate to
Table 1. Comparison of patient characteristics between responders and non-responders to steroid pulse therapy

|                | Responder | Non-responder | Rate, † | P ‡ | Rate, † | P ‡ |
|----------------|-----------|---------------|---------|-----|---------|-----|
| All            | 90        | 34            | 73 [64–80] | NA  | 73 [64–80] | NA  |
| Age, years     | 33 (19–41)| 27            | 27 [21–41] | 0.326 | 27 [21–41] | 0.326 |
| Sex            |           |               |         |     |         |     |
| Male           | 72        | 25            | 74 [64–83] | 0.469 | 74 [64–83] | 0.469 |
| Female         | 18        | 9             | 67 [46–83] | 0.532 | 67 [46–83] | 0.532 |
| Disease score³ | 1         | 5             | 63 [24–91] | 0.532 | 63 [24–91] | 0.532 |
| 2              | 14        | 3             | 82 [57–96] | 0.532 | 82 [57–96] | 0.532 |
| 3              | 71        | 28            | 71 [61–80] | 0.532 | 71 [61–80] | 0.532 |
| Cholinergic urticaria | Yes | 65 | 23 | 74 [63–83] | 0.617 | 74 [63–83] | 0.617 |
|                | No        | 25            | 11 [52–84] | 0.617 | 11 [52–84] | 0.617 |
| Delay between onset and treatment, months | 7 (4–18) | 36 | NA | 0.011 | (9–108) | 0.011 |

Data are presented as n, median (interquartile range) or percentage [95% confidence interval].

†Rate of response in the specified group. ‡For continuous variables, computed by Mann–Whitney U-test; for categorical variables, computed by Fisher’s exact test. ‡Scored according to body surface area of hypohidrosis or anhidrosis (1, 25–49%; 2, 50%–74%; 3, 75%–100%)." P < 0.05 is indicated by bold. NA, not applicable.

Table 1. Comparison of patient characteristics between responders and non-responders to steroid pulse therapy

Steroid pulse therapy for AIGA regardless of recurrence. We retrospectively collected data of 124 patients with AIGA who received steroid pulse therapy at three academic medical centers (Table S1). The male : female ratio of the patients was 3.6:1.0, and the median age was 32 years (interquartile range [IQR], 21–41). The overall age and sex distribution were similar to those in previous studies,1,3,4,5,6 but the female patients tended to be younger than the male patients (24 [IQR, 18–33] vs 33 years [IQR, 21–41]; Mann–Whitney U-test, P = 0.033). Of the 124 patients, 90 (73%) responded to the steroid pulse therapy, recovering their perspiration function within 1 month after the therapy (Table 1, Fig. 1). This response rate to steroid pulse therapy was also in accordance with a previous review of case reports of systemic steroid therapy for AIGA (78%, 25/32 patients).1,3,4,5,6 We also explored whether the patients’ characteristics affected the responsiveness and found that patients who received steroid pulse therapy earlier had a better response (Table 1, Fig. 2a).

For further exploration of factors that might affect the treatment responsiveness, we examined the effect of each course of pulse therapy because the patients often received multiple courses of pulse therapy until remission. We analyzed 184 courses of pulse therapy among the 85 patients from Tokyo Medical and Dental University hospital (average, 2.0 courses/patient; standard deviation, 1.9). The response rate to each course of pulse therapy was 43%, and the response was significantly affected by the season of treatment (Table 2). The response rate to pulse therapy in November, which is late autumn in Japan, was lower than that in spring and summer (Fig. 2b, Table S2). Figure 2(b) also shows the mean temperatures for each month in Tokyo. The response rates roughly correlated with the mean temperatures (Pearson’s correlation coefficient, r = 0.50; 95% confidence interval [CI], –0.1 to 0.8; P = 0.100). However, the response rates in spring were higher than those in autumn, although the temperatures are almost the same (discussed below). The correlation between the response rate and humidity, which is another factor that affects sweating function, was relatively weak (Pearson’s correlation coefficient, r = 0.30; 95% CI, –0.3 to 0.7; P = 0.350) (Fig. S3). We also confirmed that the response rate in autumn was lower than that in the other seasons by comparing the rates in patients who received multiple courses of pulse therapy and received the therapy in both autumn and other seasons (Fig. 2c).

The response rate to the third course of pulse therapy was lower than that to the first and second courses, but this does not necessarily mean that the effect increased or decreased depending on the number of courses (Tables 2, S3). The response rate to the third course was lower than that to the first and second courses because a substantial number of patients with a good response had completed their therapy in the first or second course (36/57 patients, 63%). The response rate after the fourth course of pulse therapy was relatively higher than that after the third course because we stopped the therapy in most of the patients who had shown no response to the first three courses (11/14 patients, 79%). We also confirmed that there was no bias between the treatment season and the number of courses (Fisher’s test, P = 0.99).

Adverse effects of steroid pulse therapy were seen in 37 of the 184 courses of pulse therapy (20%). All adverse effects were mild except in one patient, who gained more than 20% weight during prolonged treatment with an oral steroid after pulse therapy (Table S4).7,8 Psychiatric disorders (especially insomnia) and gastrointestinal disorders were the most frequent adverse effects.

Recurrence after steroid pulse therapy

To assess the true effectiveness of steroid pulse therapy, we next estimated the recurrence rate after the therapy. We conducted a time-to-event analysis involving all 57 patients who responded to the pulse therapy at Tokyo Medical and Dental University (Table S5). The traces were started on the last day of steroid pulse therapy and ended at recurrence (25/57, 44%) or were censored if the primary doctor decided to end follow up (5/57, 9%), the patient did not attend the return visit (12/57, 21%) or the end of the study was reached (21 May 2020) (16/57, 28%). Follow up to recurrence or at least 12 months was 74% complete (42/57) and median follow up in patients with no recurrence was 11.5 months (IQR, 6.6–19.0). Figure 3(a) shows the results of the analysis with a Kaplan–Meier plot. The estimated overall recurrence rate reached 48% at month 11 and almost plateaued at that time point.

Next, we explored whether the patients’ characteristics or other factors affected the recurrence rate. We found that younger patients had a greater tendency to relapse based on the univariate analyses (Table 3, Fig. 3b). Because the
presence of cholinergic urticaria may be a confounding factor (Table S5), we used a Cox proportional hazard model with age and the presence of urticaria as independent variables to estimate the relative risk. As a result, the estimated hazard ratio was 2.5 for patients aged less than 27 years (95% CI, 1.1–5.8; *P* = 0.034) and 1.1 for patients with cholinergic urticaria (95% CI, 0.4–2.9; *P* = 0.841). Moreover, the recurrence rate was highest in autumn, which indicated that autumn is the worst season for maintaining remission as well as for achieving a good treatment effect (Fig. 3c).

Finally, we estimated the net effectiveness of steroid pulse therapy considering both the response rate and recurrence rate. If we assume that a patient whose remission period is longer than 11 months is cured according to the result shown in Figure 3(a), only 21% of the patients (18/85 patients from Tokyo Medical and Dental University hospital) met the requirement. This rate is too low for estimation of the effectiveness because a certain number of patients responded to the therapy but were censored before 11 months of follow up after the therapy. We therefore estimated the recurrence rate was the worst season for maintaining remission as well as for achieving a good treatment effect (Fig. 3c).

We performed steroid pulse therapy after recurrence in 11 patients. Of those 11 patients, six (55%) recovered without subsequent relapse (median follow-up time after the second remission, 7 months [IQR, 6–8]), three (27%) temporally responded but relapsed again, and two (18%) did not respond to the therapy anymore. Based on these data, we estimated the effectiveness of steroid pulse therapy for AIGA to be approximately 57% (the second term of Equation 2 approximates the cure rate of patients who developed recurrence). We also confirmed the estimation using the Kaplan–Meier method with adaptation to our definition of cure (55% cure rate at month 23) (Fig. S4).

**DISCUSSION**

To investigate the true effectiveness of steroid pulse therapy for AIGA, we examined both the responsiveness and recurrence rate after steroid pulse therapy. The initial response rate to the therapy was 73% in our 124 patients. The estimated recurrence rate reached 48% at approximately 1 year and then plateaued based on our cohort study of 57 patients. The overall effectiveness of steroid pulse therapy was estimated to be approximately 57%. We also identified some negative factors that appear to influence the treatment effectiveness, including a longer delay between onset and treatment, and a younger age. Moreover, we revealed a strong seasonal effect on both
We do not believe that these biases are large enough to alter the decision to use steroids. Indeed, Cao and Tey reported that spontaneous remission was observed in five of 13 (38.5%) patients during several years of follow up. We might have waited for spontaneous remission if our patients had only mild symptoms; however, most of our patients had severe symptoms that restricted their activities: 80% of the patients showed severe hypohidrosis/anhidrosis (>75% of body surface area) and 71% had pain (Table 1). Steroid pulse therapy has the potential to relieve such symptoms within a few days. The decision to delay therapy must be made only after careful consideration, and the risk of a decreased therapeutic effect must be considered.

Our exploratory analysis showed that autumn is the worst season for both the treatment outcome and recurrence. The mechanism of heat adaptation may account for this seasonal difference. Because autumn is not the coldest season, the ambient temperature should not be the only reason for the seasonal difference. Body temperature regulation by sweating reportedly differs between spring and autumn, although the ambient temperatures are almost the same in these two seasons. This fact indicates that seasonal adaptation over the course of winter and summer persists in spring and autumn. In addition, long exposure to heat, such as during summer, increases sweating function but later conversely reduces sweating function.

Failure to adapt to the seasonal temperature after a hot summer, such as an overshoot of the reduction mechanism, may account for the higher risks of ineffective treatment and recurrence in autumn.

A limitation of this study may be the high proportion of censored patients who did not attend the return visit in the time-to-event analysis. We expect that most of them had no recurrence because no other medical institution in our geographic location specialized in this rare disease. If most of the censored patients had no recurrence, bias might have affected the estimation of the recurrence rate and overall effectiveness of the therapy. We therefore conducted a simulation assuming that all of the patients who dropped out of the follow up had no recurrence until the end of the observation period (May 2020). The estimated recurrence rate in this simulation was 43% at 1 year (95% CI, 30–56; representing an ~5% decrease from the original estimation), and the overall effectiveness of steroid pulse therapy was 58% (representing a 1% increase). We do not believe that these biases are large enough to reduce the credibility of our study.

### Table 2. Responses to individual courses of steroid pulse therapy

| Season of treatment | Effective | Ineffective | Rate, % | P |
|---------------------|-----------|-------------|---------|---|
| All                 | 80        | 104         | 43 [36–51] | NA |
| Post-treatment¹     |           |             |         |    |
| Yes                 | 17        | 12          | 59 [39–76] | 0.073 |
| No                  | 63        | 92          | 41 [33–49] |    |
| No. of courses      |           |             |         |    |
| 1st                 | 31        | 47          | 40 [29–51] | 0.049 |
| 2nd                 | 28        | 21          | 57 [42–71] |    |
| 3rd                 | 8         | 22          | 27 [12–46] |    |
| ≥4th                | 13        | 14          | 48 [29–68] |    |
| Interval, months²   |           |             |         |    |
| Spring              | 28        | 28          | 50 [36–64] | <0.001 |
| Summer              | 36        | 24          | 60 [28–72] |    |
| Autumn              | 7         | 27          | 21 [9–38]  |    |
| Winter              | 9         | 25          | 26 [13–44] |    |
| Interval, months³   | 2.3       | (1.3–3.9)   | 3.2 (1.4–5.8) | NA |

Data are presented as n, median (interquartile range) or percentage [95% confidence interval].

¹Rate of response in the specified group. ²For continuous variables, computed by Mann–Whitney U-test; for categorical variables, computed by Fisher’s exact test. ³Patients received oral steroid treatment after 3-day pulse therapy of i.v. steroids, typically starting with 0.5 mg/kg per day of prednisolone for 2–4 weeks. ⁴Spring, March–May; summer, June–August; autumn, September–November; winter, December–February. ⁵Interval from previous course of pulse therapy, calculated from the data of the second or later courses (number of courses of pulse therapy: 46 and 55). P < 0.05 is indicated by bold. NA, not applicable.
Another limitation of this study may be the accuracy of therapy evaluation because we did not always perform Minor’s test after steroid pulse therapy. In most cases, we conducted the primary evaluation of the therapeutic effect based on self-assessment during outpatient care and confirmed the result by performing Minor’s test before starting the next course of pulse therapy at the time of rehospitalization. We believe that the self-assessment of sweating function during follow-up was reasonably accurate (93% accuracy compared with Minor’s test for follow up) (Table S6). However, a simpler method than Minor’s test should be used to evaluate whole-body sweating function during the routine care of patients with AIGA.

In conclusion, our study revealed the precise effectiveness of steroid pulse therapy for AIGA considering both the response rate and recurrence rate. A longer period from onset to treatment and a younger age appear to be risk factors for poorer outcomes, but focusing on treatment in the proper season may increase the therapeutic effect. For example, we might encounter the need to start treatment for a patient with AIGA in autumn. In such cases, we should not abandon steroid pulse therapy before the arrival of spring even if the therapy shows no effect. It seems to take a couple of years to lose the responsiveness to steroid therapy (Fig. 2a). Therefore, to decrease the risk of adverse effects of steroids, it may be acceptable to reduce the frequency of pulse therapy during autumn and winter. However, we instead recommend increasing the frequency of pulse therapy during spring and summer.

ACKNOWLEDGMENTS: This work was supported by AMED (grant no. JP20ek0109435) and by Health and Labor Sciences Research (grant no. 19FC1009). We wish to thank Y. Kawamura for secretarial work. We also thank Angela Morben, D.V.M., E.L.S., from Edanz Group.
CONFLICT OF INTEREST:  None declared.

1 Munetsugu T, Fujimoto T, Oshima Y et al. Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan. J Dermatol 2017; 44: 394–400.

2 Munetsugu T, Fujimoto T, Satoh T et al. Evaluation of the correlation between severity of acquired idiopathic generalized anhidrosis and quality of life scores. J Dermatol 2017; 44: 747–752.

3 Murakami K, Sobue G, Terao S, Mitsuma T. Acquired idiopathic generalized anhidrosis: a distinctive clinical syndrome. J Neurol 1988; 235: 428–431.

4 Tay LK, Chong WS. Acquired idiopathic anhidrosis: A diagnosis often missed. J Am Acad Dermatol 2014; 71: 499–506.

5 Ando Y, Fuji S, Sakashita N et al. Acquired idiopathic generalized anhidrosis: clinical manifestations and histochemical studies. J Neurol Sci 1995; 132: 80–83.

6 Fukunaga A, Horikawa T, Sato M, Nishigori C. Acquired idiopathic generalized anhidrosis: possible pathogenic role of mast cells. Br J Dermatol 2009; 160: 1337–1340.

7 Sawada Y, Nakamura M, Bito T et al. Decreased expression of acetylcholine esterase in cholinergic utricaria with hypohidrosis or anhidrosis. J Invest Dermatol 2014; 134: 276–279.

8 Nakazato Y, Tamura N, Ohkuma A et al. Idiopathic pure sudomotor failure: Anhidrosis due to deficits in cholinergic transmission. Neurology 2004; 63: 1476–1480.

9 Cao R, Tey HL. Prognosis of acquired idiopathic generalized anhidrosis. J Ger Soc Dermatol 2017; 15: 940–945.

10 Yontaka A, Hishima T, Akagi K, Kishida S. Successful steroid treatment of acquired idiopathic partial hypohidrosis. J Dermatol 2006; 33: 265–267.

11 Miyazoe S, Matsuo H, Ohnishi A et al. Acquired idiopathic generalized anhidrosis with isolated sudomotor neuropathy. Ann Neurol 1998; 44: 378–381.

12 Ogino J, Saga K, Kagaya M et al. Idiopathic acquired generalized anhidrosis due to occlusion of proximal coiled ducts. Br J Dermatol 2004; 150: 589–593.

13 Ohshima Y, Yanagishita T, Ito K et al. Treatment of patients with acquired idiopathic generalized anhidrosis. Br J Dermatol 2013; 168: 430–432.

14 Asahina M, Sano K, Fujinuma Y, Kuwabara S. Investigation of antimuscarinic receptor autoantibodies in patients with acquired idiopathic generalized anhidrosis. Intern Med 2013; 52: 2733–2737.

15 Fukunaga A, Hatakeyama M, Tsujimoto M et al. Steroid treatment can improve the impaired quality of life of patients with acquired idiopathic generalized anhidrosis. Br J Dermatol 2015; 172: 537–538.

16 Japan Meteorological Agency [homepage on the internet]. 2020. Available from URL: https://www.jma.go.jp/jma/indexe.html

17 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289–300.

18 R Core Team. R: A language and environment for statistical computing. 2018. Available from URL: https://www.r-project.org/